JP Morgan analyst Michael Glick upgrades Commercial Metals (NYSE:CMC) from Neutral to Overweight.
Kadman Reports REZUROCK Was Added To National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology For Hematopoietic Cell Transplantation
Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that the National Comprehensive Cancer Network® (NCCN) added REZUROCKTM (belumosudil) tablets to its NCCN Clinical Practice Guidelines in Oncology (NCCN
